Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years

NCT00387725 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00387725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00387725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
February 29, 2008
Enrollment
127 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

healthy